Each row is a drug, each column a cancer subtype. Cells show the strongest known association for that drug in that cancer: approved clinical trial or blank. The repositionable flag means the drug appears as a synthetic-lethal repositioning candidate in cansar; it’s gene-level, not cancer-level.
| Drug | Target | Relationship | GBM | LUAD | SCLC | LUSC | OAC | OSCC | PDAC | Reposition | #cancers |
|---|---|---|---|---|---|---|---|---|---|---|---|
| adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib | AKT3 | Direct | 3 | ||||||||
| capivasertib | AKT3 | Direct | 1 | ||||||||
| adagrasib | KRAS | SSL via KRAS | yes | 2 | |||||||
| sotorasib | KRAS | SSL via KRAS | yes | 2 | |||||||
| adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib | AKT1 | SSL via AKT1 | 3 | ||||||||
| adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib | AKT2 | SSL via AKT2 | 3 | ||||||||
| arsenic trioxide | AKT1 | SSL via AKT1 | 1 | ||||||||
| arsenic trioxide, radiation therapy | AKT1 | SSL via AKT1 | 1 | ||||||||
| arsenic trioxide, temozolomide, adjuvant therapy, intensity-modulated radiation therapy, radiation therapy | AKT1 | SSL via AKT1 | 1 | ||||||||
| capivasertib | AKT1 | SSL via AKT1 | 1 | ||||||||
| capivasertib | AKT2 | SSL via AKT2 | 1 | ||||||||
| cytoreductive surgery, perifosine, temsirolimus | AKT1 | SSL via AKT1 | 1 | ||||||||
| enzastaurin, bevacizumab, enzyme-inducing antiepileptic drugs (eiaed), non-enzyme inducing antiepileptic drugs (neiaed) | AKT1 | SSL via AKT1 | 1 | ||||||||
| enzastaurin, lomustine | AKT1 | SSL via AKT1 | 1 | ||||||||
| enzastaurin, temozolomide, radiation therapy | AKT1 | SSL via AKT1 | 1 | ||||||||
| genistein, erlotinib hydrochloride, gemcitabine hydrochloride | AKT1 | SSL via AKT1 | 1 | ||||||||
| laboratory biomarker analysis, perifosine, temsirolimus, therapeutic conventional surgery | AKT1 | SSL via AKT1 | 1 | ||||||||
| perifosine | AKT1 | SSL via AKT1 | 1 |